✨
AI Summary
- Carlos Buesa explains Oryzon's LSD1 inhibition strategy for various diseases.
- Targeting epigenetics shows promise in oncology, CNS, and sickle cell disease.
- Early clinical data supports a precision epigenetics approach.
Guests on This Episode
CP
Carlos Buesa, Ph.D
1 podcast appearance